RIPK1 inhibitor, necrostatin-1, and MLKL inhibitor, necrosulfonamide, to block necroptosis; caspase-1 inhibitor, AC-YVAD-CMK, and GSDMD inhibitor, LDC7559, to prevent pyroptosis; and selective JAK1 ...

Small Molecule Therapeutic Discovery, Amgen Research, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States ...

Kaken Pharmaceutical will hand Alumis $40 million in the near term for the rights to develop a late-stage tyrosine kinase 2 (TYK2) inhibitor as a dermatology treatment in Japan. The drug in ...

This summary outlines the therapeutic mechanisms and effects of five classes of inhibitors: the caspase family, inflammasomes, RIPK1/3, GSDMD/GSMDE/MLKL and calpains in experimental models.

Get Instant Summarized Text (Gist) New inhibitors of the enzyme human 15-lipoxygenase-2 (h15-LOX-2) have been identified using computational tools and virtual screening. This enzyme is involved in ...

State Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Basic Research Center of Excellence for Natural Bioactive Molecules and Discovery of Innovative Drugs, International ...

Janus kinase inhibitors (JAKis) are an important treatment option for people with chronic inflammatory diseases such as rheumatoid arthritis, psoriasis, Crohn's disease or ulcerative colitis.